Investor Presentaiton

Oncology Hematology Cell Therapy Immunology Cardiovascular Reblozyl (Erythroid Maturation Agent) Indication Phase/Study # of Patients Design Endpoints Status CT Identifier TD & NTD Alpha-Thalassemia (Ex-US study) Phase II CA056-015 N = 177 Reblozyl 1.0 mg/kg SC Q3W • Placebo SC Q3W + Best Supportive Care Primary: ⚫ TD: ≥50% reduction in TF burden over any rolling 12 weeks between W13-W48 NTD: ≥1 g/dL Hb mean increase from baseline in W13- W24 Key secondary: • TD: No. of participants with ≥ 33% reduction from baseline in RBC transfusion burden • NTD: Change from baseline to W24 in hemoglobin in the absence of transfusion Recruiting Expected data readout 2025 NCT05664737 1L NTD Low-or Intermediate Risk Myelodysplastic Syndrome (MDS) Associated Anemia Phase III - ELEMENT-MDS N = 360 • Reblozyl 1.0 mg/kg SC Q3W Epoetin Alfa 450 IU/kg SC QW Primary: Proportion of participants during Wk 1-96 who convert to TD (≥ 3 units/16 weeks per IWG 2018) Key secondary: Mean hemoglobin increase ≥ 1.5 g/dL + TI for at least 16 wks during Wk 1-48 Recruiting Expected data readout 2027 NCT05949684 ll Bristol Myers Squibb Q3 2023 Results Not for Product Promotional Use 42

View entire presentation